Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) stock jumped 4.23% on Wednesday to $2.22 against a previous-day closing price of $2.13. With 0.27 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.38 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.2200 whereas the lowest price it dropped to was $2.1300. The 52-week range on PRTK shows that it touched its highest point at $4.95 and its lowest point at $1.60 during that stretch. It currently has a 1-year price target of $18.00. Beta for the stock currently stands at 1.48.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PRTK was up-trending over the past week, with a rise of 8.29%, but this was down by -37.46% over a month. Three-month performance dropped to -18.98% while six-month performance rose 27.59%. The stock lost -50.99% in the past year, while it has lost -50.56% so far this year. A look at the trailing 12-month EPS for PRTK yields -1.69 with Next year EPS estimates of 0.35. For the next quarter, that number is -0.09. This implies an EPS growth rate of 44.20% for this year and 130.70% for next year.
Float and Shares Shorts:
At present, 55.17 million PRTK shares are outstanding with a float of 46.32 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.64 million, which was 6.64% higher than short shares on Sep 14, 2022. In addition to Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA as the firm’s Exec. Chairman, Dr. Evan Loh FACC, FAHA, M.D. serves as its CEO & Director.
Through their ownership of 46.90% of PRTK’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 23.30% of PRTK, in contrast to 18.01% held by mutual funds. Shares owned by individuals account for 11.26%. As the largest shareholder in PRTK with 7.09% of the stake, AIGH Capital Management LLC holds 3,887,172 shares worth 3,887,172. A second-largest stockholder of PRTK, The Vanguard Group, Inc., holds 2,159,358 shares, controlling over 3.94% of the firm’s shares. General American Investors Co., I is the third largest shareholder in PRTK, holding 1,916,099 shares or 3.49% stake. With a 3.49% stake in PRTK, the General American Investors Fund is the largest stakeholder. A total of 1,916,099 shares are owned by the mutual fund manager. The Bruce Fund, which owns about 2.60% of PRTK stock, is the second-largest Mutual Fund holder. It holds 1,427,412 shares valued at 5.08 million. Vanguard Total Stock Market Index holds 2.59% of the stake in PRTK, owning 1,420,052 shares worth 5.06 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PRTK since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PRTK analysts setting a high price target of $30.00 and a low target of $11.00, the average target price over the next 12 months is $20.33. Based on these targets, PRTK could surge 1251.35% to reach the target high and rise by 395.5% to reach the target low. Reaching the average price target will result in a growth of 815.77% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PRTK will report FY 2022 earnings on 03/02/2023. Analysts have provided yearly estimates in a range of -$0.78 being high and -$1.35 being low. For PRTK, this leads to a yearly average estimate of -$1.14. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Paratek Pharmaceuticals Inc. surprised analysts by -$0.09 when it reported -$0.38 EPS against a consensus estimate of -$0.29. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is $0.27 and the low estimate is -$0.26. The average estimate for the next quarter is thus -$0.07.
Summary of Insider Activity:
Insiders traded PRTK stock several times over the past three months with 5 Buys and 5 Sells. In these transactions, 92,750 shares were bought while 27,266 shares were sold. The number of buy transactions has increased to 22 while that of sell transactions has risen to 24 over the past year. The total number of shares bought during that period was 1,370,704 while 359,311 shares were sold.